logo
Indian diet trap for IBS: Foods that could be making your gut health worse

Indian diet trap for IBS: Foods that could be making your gut health worse

Hindustan Times28-04-2025

Irritable Bowel Syndrome (IBS) is a common digestive disorder affecting approximately 7% of the Indian population. This functional gastrointestinal disorder manifests through symptoms like abdominal pain, bloating, gas and irregular bowel movements—including diarrhea, constipation, or alternating between both.
In an interview with HT Lifestyle, Pariksha Rao, Director-Nutrition and Medical Affairs at The Good Bug, shared, 'Stress and sleep deprivation can trigger or worsen IBS symptoms. Unlike other digestive diseases, IBS doesn't cause physical damage to the digestive tract, but significantly impacts quality of life due to its disruption of the brain-gut connection.'
April is marked as IBS Awareness Month, aiming to spread more knowledge about this condition. Awareness is key, as many people suffer without realising they have IBS or what they can do to manage it.
Pariksha Rao said, 'Despite its prevalence in India many suffer without proper diagnosis or management strategies. Modern lifestyles, increasing stress levels and changing dietary patterns have contributed to rising cases across the country. There's also increasing evidence that IBS is closely linked to the gut microbiome and the gut-brain axis — the two-way communication system between our brain and digestive system. When this system is out of balance, it can make the gut overly sensitive or change how the muscles in the intestines move, causing IBS symptoms.'
Diet plays a crucial role in managing IBS. Pariksha Rao revealed, 'Indian food is often rich in spices, fiber, and fermented ingredients, which can either help or harm those with IBS, depending on how the body reacts. Traditional diets may offer some relief, but modern diets — which are increasingly full of processed foods, sugar, and fats — can make symptoms worse.'
She explained, 'One of the major triggers for IBS is food that is high in FODMAPs [Fermentable Oligosaccharides (e.g. fructans and galacto-oligosaccharides) Disaccharides (e.g. lactose) Monosaccharides (e.g. excess fructose) and Polyols (e.g. sorbitol and mannitol)] — short-chain carbohydrates that are poorly absorbed in the small intestine. Common FODMAP foods in the Indian diet include garlic, onions and fruits like apples. These foods ferment in the gut, creating gas and causing bloating, pain and irregular bowel movements.'
The expert added, 'Caffeine and carbonated drinks are also triggers for many IBS patients. They can stimulate the gut too much and lead to diarrhea or gas. Artificial sweeteners like sorbitol, xylitol, and mannitol — often found in sugar-free products — are also known to cause bloating and discomfort because they are not fully absorbed in the gut.'
Pariksha Rao suggested, 'A balanced diet, rich in the right kind of fiber and low in irritants, can make a big difference. Probiotics — found in yogurt, kefir, or supplements — can help restore a healthy gut microbiome and reduce symptoms. However, fiber intake should be monitored. For people with IBS-D (diarrhea-dominant IBS), too much fiber can worsen symptoms.'
According to her, what works best is a personalised approach. Pariksha Rao said, 'Some people may benefit from reducing dairy or gluten, while others might need to stay away from specific vegetables or fruits. Eating smaller meals, staying hydrated, and avoiding foods that are hard to digest or cause gas are all recommended steps. Keeping a food diary can also help identify which foods trigger symptoms.'
Talking about a holistic approach to gut health, Pariksha Rao asserted, 'IBS is a complex condition with no one-size-fits-all solution but by understanding how diet and stress influence gut health, individuals can take control of their symptoms. In India, as awareness grows and more people seek professional advice, better management is becoming possible. With the right combination of diet, probiotics, and stress-relief practices, people living with IBS can enjoy a better quality of life. As we observe IBS Awareness Month this April, it's the perfect time to start making thoughtful food choices and take care of both our gut and mind.'
Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

KKR-backed IVI to buy ART Fertility Clinics for $450 million
KKR-backed IVI to buy ART Fertility Clinics for $450 million

Economic Times

time3 hours ago

  • Economic Times

KKR-backed IVI to buy ART Fertility Clinics for $450 million

Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million."For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well."IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals.A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to is the advisor in the is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%.India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.

Seminar on MBBS, global education pathways in Pune draws enthusiastic response
Seminar on MBBS, global education pathways in Pune draws enthusiastic response

Time of India

time4 hours ago

  • Time of India

Seminar on MBBS, global education pathways in Pune draws enthusiastic response

1 2 P une: A large gathering of aspiring students and parents attended an informative Mission Admission seminar organised by The Times of India jointly with The Astute Academy at Dr. Kalmadi Shamarao Junior College auditorium on Sunday. Conducted by Tushar Vinod Deoras, a former BARC scientist and chairman of Astute Academy, the seminar aimed to demystify the complexities of Indian and international admissions for MBBS and higher education. The first session focused on the Indian MBBS admission process, offering clarity for students with NEET scores as low as 200. Attendees also learned about affordable pathways to study medicine in the United States through structured Indo-American university collaborations. The second session delved into undergraduate and postgraduate admissions in the US and Germany. Parents and students were provided with detailed guidance on securing spots at prestigious universities abroad. During the first session, Deoras shared a wealth of information. He pointed out that many private medical colleges offer donation-free management quota merit seats. He explained fee structures, wherein funding is controlled by govt, and proposed to students tripartite Indo-American university partnered systems, which provide affordable, sophisticated modern medical education in the US and subsequently offer employer-relevant value around the globe. The second session was about undergraduate and postgraduate courses offered in the US and Germany, particularly emphasising on Ivy League schools and Germany's technical universities. Deoras noted how flexible and multidisciplinary the US system is, with more emphasis on career focus than rigid course structures. He urged students to start building their profiles as early as Std IX and to apply to international universities at least one year in advance, as most operate on a first-come, first-served basis. He said, "Quality education and a successful career are a student's fundamental right. Students and parents should not judge countries by stereotypes but understand which system aligns best with the student's goals." A highlight of the seminar was its interactive nature. One parent shared, "The session was very enlightening. Many doubts regarding my son's education were resolved, and I feel much more at peace now." Another participant raised a query about dentistry as a career path, to which Deoras responded that it remains an underappreciated but highly rewarding field in India. While initial years in practice may be challenging, dentistry offers significant long-term growth and financial prospects. Deoras also addressed several audience questions about state-wise admission quotas for MBBS, the application process for foreign universities, and the admission timelines and requirements for medical education abroad. The seminar concluded with a positive response from the audience who appreciated the transparency, practical guidance, and motivational approach.

KKR-backed IVI to buy ART Fertility Clinics for $450 million
KKR-backed IVI to buy ART Fertility Clinics for $450 million

Time of India

time4 hours ago

  • Time of India

KKR-backed IVI to buy ART Fertility Clinics for $450 million

KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin America. Both parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June end. As with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) valuation. ART Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and India. Live Events With clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Capital. ART Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and Faridabad. Led by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine years. According to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million. "For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well." IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals. A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to queries. Moelis is the advisor in the transaction. India is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in Europe. Infertility affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and pollution. According to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%. India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall Clinic. Nova IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and TPG. Similarly, homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store